Frazier Life Sciences Management L.P. Purchases New Stake in Maze Therapeutics, Inc. $MAZE

Key Points

• Frazier Life Sciences Management L.P. acquired 4,129,001 shares of Maze Therapeutics, Inc. ($MAZE), worth approximately $45.46 million, making it the fund's 12th largest holding.
• Maze Therapeutics reported a quarterly earnings per share (EPS) of ($0.77), exceeding analysts' estimates of ($0.79) by $0.02.
• Wall Street analysts have a consensus rating of "Buy" for Maze Therapeutics, with an average price target of $25.60.

Frazier Life Sciences Management L.P. bought a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 4,129,001 shares of the company's stock, valued at approximately $45,460,000. Maze Therapeutics makes up about 2.1% of Frazier Life Sciences Management L.P.'s portfolio, making the stock its 12th biggest position. Frazier Life Sciences Management L.P. owned 9.43% of Maze Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. TRV GP IV LLC acquired a new position in Maze Therapeutics during the 1st quarter valued at approximately $66,874,000. Matrix Capital Management Company LP acquired a new position in Maze Therapeutics during the 1st quarter valued at approximately $27,373,000. Alphabet Inc. acquired a new position in Maze Therapeutics during the 1st quarter valued at approximately $26,561,000. General Catalyst Group Management LLC acquired a new position in Maze Therapeutics during the 1st quarter valued at approximately $11,405,000. Finally, TRV GP V LLC acquired a new position in Maze Therapeutics during the 1st quarter valued at approximately $10,468,000.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. BTIG Research began coverage on Maze Therapeutics in a research report on Tuesday, September 2nd. They set a "buy" rating and a $30.00 price target for the company. Wedbush began coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price target for the company. Finally, HC Wainwright began coverage on Maze Therapeutics in a research report on Wednesday, July 23rd. They set a "buy" rating and a $34.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $26.33.

Maze Therapeutics Stock Up 5.6%

Shares of MAZE traded up $0.84 during midday trading on Friday, reaching $15.88. The stock had a trading volume of 309,623 shares, compared to its average volume of 310,347. The firm's 50 day moving average price is $14.55 and its 200-day moving average price is $12.01. Maze Therapeutics, Inc. has a 52 week low of $6.71 and a 52 week high of $19.19.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Maze Therapeutics Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.